Radiation Therapy With or Without Temozolomide in Treating Women With Brain Metastases and Breast Cancer
Radiation Therapy With or Without Temozolomide in Treating Women With Brain Metastases and Breast Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in
 chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells,
 either by killing the cells or by stopping them from dividing. It is not yet known whether
 radiation therapy is more effective when given alone or together with temozolomide in
 treating brain metastases secondary to breast cancer.

 PURPOSE: This randomized phase II trial is studying how well radiation therapy given together
 with temozolomide works compared with radiation therapy given alone in treating women with
 brain metastases and breast cancer.
OBJECTIVES:

 Primary

 -  Compare the objective response rate at 6 weeks in women with brain metastases secondary
 to breast cancer treated with radiotherapy with vs without temozolomide.

 Secondary

 -  Evaluate the tolerability.

 -  Compare the duration of response.

 -  Compare local progression-free survival.

 -  Compare overall survival.

 OUTLINE: This is a multicenter study. Patients are randomized to 1 of 2 treatment arms.

 -  Arm I: Patients undergo isocentric radiotherapy to the brain 5 times a week for 2 weeks.

 -  Arm II: Patients undergo radiotherapy as in arm I and receive oral temozolomide once
 daily for 2 weeks.

 After completion of study treatment, patients are followed at 3 and 6 months and then every 6
 months for 2 years.
DISEASE CHARACTERISTICS:

 -  Diagnosis of breast cancer

 -  Unresectable disease or patient refused surgery

 -  Must have brain metastases

 PATIENT CHARACTERISTICS:

 -  WHO performance status 0-2

 -  ANC ≥ 1,500/mm³

 -  Platelet count ≥ 100,000/mm³

 -  Liver transaminases ≤ 1.5 times upper limit of normal (ULN)

 -  Creatinine < 1.5 times ULN

 -  Not pregnant or nursing

 -  Fertile patients must use effective contraception

 -  No carcinomatous meningitis

 -  No history of cancer except for basal cell carcinoma of the skin or carcinoma in situ
 of the cervix

 -  No other serious concurrent disease that is, in the opinion of the investigator,
 likely to interfere with study evaluation and treatment

 -  No contraindications to treatment with temozolomide

 -  No psychological, familial, social, or geographic situations that preclude clinical
 follow up

 -  No patient deprived of liberty or under guardianship

 PRIOR CONCURRENT THERAPY:

 -  No prior brain radiotherapy

 -  At least 10 days since prior chemotherapy